Research
A new report from the Bipartisan Policy Center makes recommendations on modernizing the U.S. public healthcare systems in light of the challenges the country has faced during the COVID-19 pandemic.
The report, Public health Forward: Modernizing the U.S. Public Health System, outlines critical... Read More »
Results from non-human primate testing of a Soligenix, Inc.-developed Bivalent Thermostabilized Filovirus vaccine, released this week, suggested 100 percent protection provided against the Sudan ebolavirus among dosed non-human primates.
The single vial vaccine is meant to target both the... Read More »
A 13-10 vote by the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) set the stage for recommending Emergency Use Authorization of the Merck and Ridgeback Biotherapeutics oral COVID-19 antiviral molnupiravir this week.
The narrow backing followed a... Read More »
Moving quickly to address concerns raised by the Omicron COVID-19 variant, following its discovery last week, INOVIO announced it will evaluate two of its COVID-19 DNA vaccine candidates against the variant and has begun pre-clinical development of another specifically tailored to it.
Omicron... Read More »
Results of a study on molnupiravir, an investigational oral antiviral developed by Merck and Ridgeback Biotherapeutics for use against COVID-19, showed this week that the drug cuts the risk of hospitalization or death by approximately 3 percent.
The trial of 1,433 participants focused on those... Read More »
Moderna announced last week a strategy for addressing the new Omicron variant of COVID-19, including a new booster vaccine and studies of boosters that have already anticipated its mutations.
The rushed strategy announcement came in the wake of closing borders and the World Health... Read More »
The World Health Organization (WHO) COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) recently reached a joint licensing agreement with the Spanish National Research Council (CSIC) for a non-exclusive COVID-19 serological antibody test.
The CSIC-developed test, to be... Read More »
In facing down a future of potential biological dangers, a new report from authors at NTI | bio recommended concrete action at the national and international level, from new oversight agencies to process overhauls and funding, to improve prevention and response.
In “Strengthening Global... Read More »
A new report from the CommuniVax Coalition has found that while progress has been made regarding equity in the COVID-19 vaccination campaign, more work is needed.
Led by the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health and the Department of Anthropology at... Read More »
Building on the success of its COVID-10 vaccine testing network to date, the Coalition for Epidemic Preparedness Innovations (CEPI) announced this week that it will expand its centralized testing capabilities to the development of vaccines for other epidemic and pandemic diseases.
CEPI’s... Read More »
Cybersecurity and Infrastructure Security Agency (CISA) personnel said the agency has issued an Infrastructure Dependency Primer (IDP) to aid state, local, tribal, and territorial planners in gaining infrastructure dependency insight.
The IDP resource supplements CISA’s recently published... Read More »
A bicameral effort from United States Rep. Rosa DeLauro (D-CT) and Sen. Edward Markey (D-MA) rebirthed the Flu Vaccine Act last week, which proposes a $1 billion investment into the National Institutes of Health (NIH) for research of a universal flu vaccine.
Such a vaccine would theoretically... Read More »
The Coalition for Epidemic Preparedness Innovations (CEPI) committed another $36.9 million to expand a contract with Clover Biopharmaceuticals and support the development of its COVID-19 vaccine candidate, SCB-2019, for use as a booster.
The new injection of funding increases CEPI’s investment... Read More »
The U.S. Department of Defense (DoD) has identified Anchorage, Alaska, as the sole candidate city to host the Ted Stevens Center for Arctic Security Studies.
The DoD would continue to navigate the Department of the Air Force Strategic Basing process to evaluate facilities within Anchorage to... Read More »
Dosing of the first volunteers for a Phase 1b clinical trial of Ebola vaccine candidate INO-4201 began this week to assess whether the vaccine could function as a booster for healthy, previously vaccinated patients.
The latest study followed positive results from pre-clinical and Phase 1 trials... Read More »
The United Nations-backed Medicines Patent Pool (MPP) gained access to Pfizer Inc.’s COVID-19 oral antiviral treatment candidate PF-07321332 this week, enabling the organization to produce and distribute the drug to generic sub-licensers for greater global access.
MPP intends to increase... Read More »
Northrop Grumman recently attained a Ground Based Strategic Deterrent (GBSD) first-stage solid rocket motor manufacturing milestone by successfully executing the first insulation and case wind processes.
“Working closely with the Air Force and nationwide team of industry partners, we continue... Read More »
National Security Agency (NSA) recently announced a partnership with the National Cryptologic Foundation to strengthen domestic cybersecurity education and cybersecurity job possibilities.
The collaboration is expected to promote a deeper understanding of prior domestic cryptologic successes;... Read More »
Data from the latest global survey on implementation of the Global Action Plan on addressing antimicrobial resistance (AMR) showed that more countries than ever are determined to fight AMR, but also major setbacks caused by the COVID-19 pandemic.
Of the 163 countries that responded to the survey... Read More »
With approval from the U.S. Food and Drug Administration (FDA) now in hand, INOVIO intends to proceed with a Phase 3 segment of its INNOVATE trial for the COVID-19 vaccine candidate INO-4800 in the United States.
Authorization followed a partial clinical hold on the candidate, while the FDA... Read More »
For at least eight months following a single dose, the REGEN-COV COVID-19 drug cocktail developed by Regeneron Pharmaceuticals, Inc. could provide affiliated risk reductions of 81.6 percent, according to a new analysis of a Phrase 3 trial.
That trial, jointly run by Regeneron and the National... Read More »
Reckoning with the more the 750,000 Americans killed by the COVID-19 pandemic, the failures that stalked response, and the threat of future outbreaks, a bipartisan collection of four senators introduced a new bill last week to build a 9/11-style commission charged with investigating the outbreak... Read More »
Interim data from Pfizer Inc.’s novel COVID-19 antiviral candidate, PAXLOVID, revealed an oral treatment with the ability to cut the risk of hospitalization and death by as much as 89 percent among adult patients.
These results, pulled from the randomized Phase 2/3 EPIC-HR (Evaluation of... Read More »
The Cybersecurity and Infrastructure Security Agency (CISA) has issued guidance to prioritize remediation of vulnerabilities presently actively exploited by adversaries.
Binding Operational Directive (BOD) 22-01 - Reducing the Significant Risk of Known Exploited Vulnerabilities establishes a... Read More »
The antiviral Molnupiravir became the first oral treatment for COVID-19 to receive authorization this week, winning approval from the U.K.’s Medicines and Healthcare Products Regulatory Agency for treatment of mild-to-moderate COVID-19 cases in adults.
Specifically, users must have had at... Read More »
The World Health Organization (WHO) made its eighth emergency use listing (EUL) for a COVID-19 vaccine this week, granting that honor to Bharat Biotech’s COVAXIN.
COVAXIN is formulated from an inactivated SARS-CoV-2 -- the virus that causes COVID-19 -- antigen. Use of the vaccine by adults was... Read More »
As world leaders gather in Glasgow for the UN Climate Change Conference, COP26, a new global partnership has formed to focus on the impact of climate change on terrorism, the group said Tuesday.
The National Consortium for the Study of Terrorism and Responses to Terrorism (START), Pool Re... Read More »
A Q2 Solutions Co., Ltd. lab facility in Beijing, China, became the first East Asian lab to join the Coalition for Epidemic Preparedness Innovations’ (CEPI) centralized COVID-19 lab network this week.
“I am delighted to today welcome Q2 Solutions’ facility in Beijing to this group of... Read More »
The failures, successes, and lessons learned from the rollout of COVID-19 vaccines should be incorporated immediately into future pandemic vaccine planning if the world hopes to avoid the delays and pitfalls of the modern ecosystem, according to a new report from the Johns Hopkins Center for Health... Read More »
The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) said two inventors within the National Urban Security Technology Laboratory (NUSTL) have received remote alarm patents.
Electronics engineer Norman Chiu and physicist Paul Goldhagen were granted U.S. Patent... Read More »
A new partnership between the Biomedical Advanced Research and Development Authority (BARDA) and RIVANNA seeks to develop the company’s Accuro XV device for the release of a portable 3D fracture detection and diagnosis system without radiation.
The rapid-working system is based on ultrasound... Read More »
In collaboration with the Indianapolis Metropolitan Police Department (IMPD), the Defense Advanced Research Projects Agency’s (DARPA) SIGMA+ program announced Friday it had recently concluded a three-month-long pilot study of sensors intended to support early detection of weapons of mass... Read More »
Reckoning with the threat of diseases present and future, the Biomedical Advanced Research and Development Authority (BARDA) announced a new collaboration last week with BD (Becton, Dickinson and Company) to develop and win approval for diagnostics capable of identifying COVID-19, influenza, as... Read More »
According to a new report from the Global Preparedness Monitoring Board (GPMB), the world is broken in its inequality, division, and lack of accountability, making a health emergency ecosystem incapable of ending the COVID-19 pandemic or preventing another.
The opportunity for reform is... Read More »
Biotechnology company INOVIO finished enrollment for a West Africa-based Phase 1B clinical trial of INO-4500, its DNA vaccine candidate for Lassa Fever, this week.
A full complement of 220 participants will participate in this first trial for a Lassa fever vaccine in West Africa. The area was... Read More »
